|
|
|
|
|
29.05.26 - 11:15
|
CSPC PHARMA Anbenitamab (Ennituo) Approved for Marketing (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) announced that Anbenitamab Injection (brand name: Ennituo), co-developed by Shanghai JMT-BIO Technology Co., Ltd., a subsidiary of the Company, and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., has received marketing authorisation from the National Medical Products Administration of the People’s Rep......
|
|
|
28.05.26 - 13:03
|
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York (GlobeNewswire EN)
|
|
|
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company's recent clinical and corporate updates....
|
|
|
28.05.26 - 08:15
|
UBS: CSPC PHARMA 1Q26 Net Profit Misses; Revenue Beats; Rated Buy (AAStocks)
|
|
|
UBS published a report stating that CSPC PHARMA (01093.HK) recorded revenue of RMB6.5 billion in 1Q26, down 7.8% YoY, exceeding both the banks and market expectations. Net profit fell 41.8% YoY to RMB860 million, below the banks and market forecasts. Excluding the impact of licensing fee income, net profit declined 7.3% YoY to R......
|
|
|
|
|
|
|
27.05.26 - 11:15
|
UNI MEDICAL Subsidiary Completes Issuance of RMB300 million Notes (AAStocks)
|
|
|
UNI MEDICAL (02666.HK) announced that its wholly owned subsidiary, Genertec Universal International Leasing, has completed the issuance of the first tranche of RMB300 million notes in China today (27th).The first tranche of notes will mature in two years from today, carrying a fixed interest rate of 1.82%. (jl/da)~AASTOCKS Finan......
|
|
|
27.05.26 - 07:30
|
CSPC PHARMA Tumbles ~8% as 1Q Profit Slides 40% YoY (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) closed at HKD7.26 at midday, down 2.42%. After announcing at noon that its 1Q26 profit declined by 40% YoY, the stock extended losses in the afternoon and last posted at HKD6.86, down 7.8%, with turnover of 64.4347 million shares, involving HKD462 million.~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
27.05.26 - 06:30
|
CSPC PHARMA 1Q26 Basic Profit Falls 40.3% YoY to RMB842 million (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) announced its results for 1Q26 ended March. Revenue amounted to RMB6.465 billion, down 7.8% YoY. Net profit was RMB860 million, down 41.8% YoY; EPS was RMB0.0754.During the period, excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation ex......
|
|
|
|
|
25.05.26 - 10:00
|
Hang Seng Index review to boost market capitalisation by 4.5 per cent: Goldman Sachs (SCMP)
|
|
|
The latest quarterly review of the Hang Seng Index will likely boost the capitalisation of the benchmark of Hong Kong stocks by 4.5 per cent and attract buying of stock including Tencent Holdings and BeOne Medicine, according to Goldman Sachs.
The market capitalisation of the Hang Seng Index is expected to rise to US$2.15 trillion after the review result showed on Friday that biotech firm BeOne Medicine, Aluminum Crop of China (Chalco) and parcel delivery firm J&T Global Express would join the......
|
|
|
|
|
|
|
22.05.26 - 16:54
|
China AI firms Zhipu, MiniMax to join Hong Kong′s Hang Seng Tech Index (SCMP)
|
|
|
Chinese AI firms MiniMax Group and Knowledge Atlas Technology – better known as Zhipu AI – will join the Hang Seng Tech Index next month.
Their inclusion follows investor criticism that the city's primary technology gauge has underperformed by missing out on the global artificial intelligence boom.
Concurrently, Shanghai-based courier J&T Global Express, lightweight metal giant Aluminum Corp of China and Beijing-founded global drug firm BeOne Medicines will join the benchmark Hang Seng Index.......
|
|
|
22.05.26 - 14:36
|
Invesco Ltd: Form 8.3 - Advanced Medical Solutions Group PLC; Opening Position disclosure (Cision)
|
|
|
FORM 8.3
OPENING POSITION DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY
INFORMATION
(a) Full name of Invesco Ltd.
discloser:
(b) Owner or
controller of
interests and
short
positions
disclosed, if
different
from 1(a):
The naming of
nominee or
vehicle
companies is
insufficient.
For a trust,
the
trustee(s),
settlor and...
|
|
|
|
|
|
|
|
|
|
|
21.05.26 - 17:06
|
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial (GlobeNewswire EN)
|
|
|
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
